Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$9.39
-0.16 (-1.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $170.3M · quality 73.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
18.8x
↓EV/EBITDA
11.5x
↓ROE
15.8%
↑Gross Margin
61.5%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.7%
FCF CAGR
-15.5%
FCF margin
8.9%
FCF / Net income
0.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.14B · net income $232.9M · FCF $101.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.14B | $1.14B | $1.30B | $1.32B | $1.40B |
| Net Income | $232.9M | $232.9M | $246.2M | $214.0M | $177.0M |
| EBITDA | $334.7M | $334.7M | $329.7M | $264.8M | $223.5M |
| EPS | 0.54 | 0.54 | 0.57 | 0.50 | 0.41 |
| Gross Margin | 61.5% | 61.5% | 54.2% | 50.8% | 52.6% |
| Operating Margin | 22.8% | 22.8% | 21.7% | 11.0% | 12.0% |
| Net Margin | 20.5% | 20.5% | 18.9% | 16.2% | 12.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 |
| Current Ratio | 3.74 | 3.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $101.6M | $101.6M | $314.6M | $170.3M | $168.5M |
| Returns | |||||
| ROE | 15.8% | 15.8% | 17.8% | 16.0% | 14.5% |
| Valuation | |||||
| P/E | 18.78 | 18.78 | 16.84 | 20.46 | 40.34 |
| EV/EBITDA | 11.50 | 11.50 | 11.93 | 15.55 | 29.65 |
| P/B | 2.74 | 2.74 | 2.99 | 3.27 | 5.85 |
| Growth & Yield | |||||
| Revenue Growth | -12.7% | -12.7% | -1.7% | -5.4% | — |
| EPS Growth | -5.3% | -5.3% | 14.0% | 22.0% | — |
| Dividend Yield | 3.4% | 3.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.6%
EPS terminal req.
$0.83
Spread vs growth
-20.8%
5Y implied EPS CAGR
13.3%
EPS terminal req.
$1.01
Spread vs growth
-18.6%
10Y implied EPS CAGR
11.6%
EPS terminal req.
$1.62
Spread vs growth
-16.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.8%
Start / end P/E
19.0x → 17.4x
EPS bridge
0.57 → 0.54
Residual
+0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.